Proenzyme Therapy

Propanc Biopharma Lines Up Up to $100 Million From Hexstone to Launch Digital-Asset Treasury and Speed PRP Toward Trials

Investors reacted to dilution risk as the deal leaves up to $99 million available over the next 12 months.